Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4994370 | 0.89 | NPC1 (0.60) | RIPK1NPC1RAB9AALDH1A1HTT | |
| SCHEMBL5001919 | 0.88 | NPC1 (0.58) | RIPK1NPC1RAB9AALDH1A1HTT | |
| SCHEMBL5001883 | 0.86 | NPC1 (0.57) | RIPK1NPC1RAB9AALDH1A1HTT | |
| SCHEMBL13060159 | 0.84 | RIPK1 (0.70) | RIPK1NPC1RAB9AALDH1A1HTT | |
| SCHEMBL20418994 | 0.84 | RIPK1 (0.70) | RIPK1HPGD | |
| SCHEMBL17882259 | 0.83 | RIPK1 (1.00) | RIPK1NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL29912660 | 0.83 | RIPK1 (1.00) | RIPK1ALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL29912603 | 0.83 | RIPK1 (1.00) | RIPK1NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL17882252 | 0.83 | RIPK1 (1.00) | RIPK1ALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL14153985 | 0.80 | RIPK1 (0.65) | RIPK1KMT2AMEN1P2RX7HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135718-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2019-05-09 | — | — | US | disclosed |
| US-20170305824-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2017-10-26 | — | — | US | disclosed |
| US-20170305824-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2017-10-26 | — | — | US | disclosed |
| US-9586880-B2 | Small molecule inhibitors of necroptosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586880-B2 | Small molecule inhibitors of necroptosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-07 | — | — | US | disclosed |
| EP-3000468-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | President and Fellows of Harvard College (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20140024657-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024657-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120122889-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122889-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010075561-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122889-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | TNF, TNFRSF1A, RIPK1 | RIPK1 3/4885NPC1 3177/4885RAB9A 2330/4885 |
| US-20170305824-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | TNF, TNFRSF1A, RIPK1 | RIPK1 3/4885NPC1 3139/4885RAB9A 2267/4885 |
| US-20190135718-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | TNF, TNFRSF1A, RIPK1 | RIPK1 3/4885NPC1 3139/4885RAB9A 2267/4885 |
| US-20140024657-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | TNF, TNFRSF1A, RIPK1 | RIPK1 3/4885NPC1 3139/4885RAB9A 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.